Treatment of OAB and urinary incontinence is highly dependent on the needs and capabilities of the patient. Treatment frequently begins with physiological interventions such as pelvic muscle rehabilitation and fluid and dietary modifications. These programs may be combined with
biofeedback and behavioral therapies such as bladder training and toileting assistance. When physiological and behavioral therapies prove insufficient, second line pharmacological agents may be used to reduce the overactivity of the detrusor muscle. For patients with overactive bladder (OAB) and urinary incontinence who are inadequately managed by pharmacologic therapies, or are not suitable candidates for more invasive therapies, there is an unmet medical need for a less invasive, more convenient OAB treatment options. BOTOX® (Botulinum Toxin Type A) purified neurotoxin complex (United States adopted name onabotulinumtoxinA), administered via intradetrusor injections, is currently approved in more than 80 countries worldwide for the treatment of overactive bladder (OAB) with symptoms of
urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication. A new route of administration, intravesical instillation, is being developed for the treatment of OAB and urinary incontinence.
For more information, call
Cyn3rgy Research at
503 907 2179 x3
Sign Up for one of our studies!